お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は多発性硬化症の治療市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートは多発性硬化症の治療の主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界の多発性硬化症の治療市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートは多発性硬化症の治療のメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別に多発性硬化症の治療市場を分類しています。本研究に含まれる主な企業は：Novartis、Teva Pharmaceuticals、Sanofi Genzyme、Bayer、Pfizer、Biogen Idec、Merck、AbbVie

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Beta Interferon
    Corticosteroids
    Monoclonal Antibodies
    Antineoplastic Agents
    Others

用途別の市場セグメント：
    Hospital Pharmacies
    Retail Pharmacies
    e-Commerce

本レポートの詳細内容
世界の多発性硬化症の治療市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、多発性硬化症の治療タイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業の多発性硬化症の治療収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界の多発性硬化症の治療市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、多発性硬化症の治療市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

多発性硬化症の治療のレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：多発性硬化症の治療のレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：多発性硬化症の治療の世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章多発性硬化症の治療企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：多発性硬化症の治療の各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：多発性硬化症の治療の主要企業の概要を提供し、製品の説明と仕様、多発性硬化症の治療の収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the disease can cause the nerves themselves to deteriorate or become permanently damaged.
Market Analysis and Insights: Global Multiple Sclerosis Therapeutics Market
The global Multiple Sclerosis Therapeutics market is projected to grow from US$ 17400 million in 2024 to US$ 19600 million by 2030, at a Compound Annual Growth Rate (CAGR) of 2.0% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Multiple Sclerosis Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of Multiple Sclerosis Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Multiple Sclerosis Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Multiple Sclerosis Therapeutics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Multiple Sclerosis Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Distribution Channel, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Multiple Sclerosis Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Novartis, Teva Pharmaceuticals, Sanofi Genzyme, Bayer, Pfizer, Biogen Idec, Merck and AbbVie, etc.

Market Segmentation
By Company
    Novartis
    Teva Pharmaceuticals
    Sanofi Genzyme
    Bayer
    Pfizer
    Biogen Idec
    Merck
    AbbVie

Segment by Type
    Beta Interferon
    Corticosteroids
    Monoclonal Antibodies
    Antineoplastic Agents
    Others

Segment by Distribution Channel
    Hospital Pharmacies
    Retail Pharmacies
    e-Commerce

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Multiple Sclerosis Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Multiple Sclerosis Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Distribution Channel, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Distribution Channel and by country, revenue for each segment.
Chapter 7: Europe by Type, by Distribution Channel and by country, revenue for each segment.
Chapter 8: China by Type, and by Distribution Channel, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Distribution Channel and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Distribution Channel and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Multiple Sclerosis Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global Multiple Sclerosis Therapeutics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Beta Interferon
    Table 3. Key Players of Corticosteroids
    Table 4. Key Players of Monoclonal Antibodies
    Table 5. Key Players of Antineoplastic Agents
    Table 6. Key Players of Others
    Table 7. Global Multiple Sclerosis Therapeutics Market Size Growth Rate by Distribution Channel (US$ Million), 2019 VS 2023 VS 2030
    Table 8. Global Multiple Sclerosis Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 9. Global Multiple Sclerosis Therapeutics Market Size by Region (2019-2024) & (US$ Million)
    Table 10. Global Multiple Sclerosis Therapeutics Market Share by Region (2019-2024)
    Table 11. Global Multiple Sclerosis Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 12. Global Multiple Sclerosis Therapeutics Market Share by Region (2025-2030)
    Table 13. Multiple Sclerosis Therapeutics Market Trends
    Table 14. Multiple Sclerosis Therapeutics Market Drivers
    Table 15. Multiple Sclerosis Therapeutics Market Challenges
    Table 16. Multiple Sclerosis Therapeutics Market Restraints
    Table 17. Global Multiple Sclerosis Therapeutics Revenue by Players (2019-2024) & (US$ Million)
    Table 18. Global Multiple Sclerosis Therapeutics Revenue Share by Players (2019-2024)
    Table 19. Global Top Multiple Sclerosis Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Sclerosis Therapeutics as of 2023)
    Table 20. Global Multiple Sclerosis Therapeutics Industry Ranking 2022 VS 2023 VS 2024
    Table 21. Global 5 Largest Players Market Share by Multiple Sclerosis Therapeutics Revenue (CR5 and HHI) & (2019-2024)
    Table 22. Global Key Players of Multiple Sclerosis Therapeutics, Headquarters and Area Served
    Table 23. Global Key Players of Multiple Sclerosis Therapeutics, Product and Application
    Table 24. Global Key Players of Multiple Sclerosis Therapeutics, Product and Application
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Multiple Sclerosis Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 27. Global Multiple Sclerosis Therapeutics Revenue Market Share by Type (2019-2024)
    Table 28. Global Multiple Sclerosis Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 29. Global Multiple Sclerosis Therapeutics Revenue Market Share by Type (2025-2030)
    Table 30. Global Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2019-2024) & (US$ Million)
    Table 31. Global Multiple Sclerosis Therapeutics Revenue Share by Distribution Channel (2019-2024)
    Table 32. Global Multiple Sclerosis Therapeutics Forecasted Market Size by Distribution Channel (2025-2030) & (US$ Million)
    Table 33. Global Multiple Sclerosis Therapeutics Revenue Share by Distribution Channel (2025-2030)
    Table 34. North America Multiple Sclerosis Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 35. North America Multiple Sclerosis Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 36. North America Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2019-2024) & (US$ Million)
    Table 37. North America Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2025-2030) & (US$ Million)
    Table 38. North America Multiple Sclerosis Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 39. North America Multiple Sclerosis Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 40. North America Multiple Sclerosis Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 41. Europe Multiple Sclerosis Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 42. Europe Multiple Sclerosis Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 43. Europe Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2019-2024) & (US$ Million)
    Table 44. Europe Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2025-2030) & (US$ Million)
    Table 45. Europe Multiple Sclerosis Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 46. Europe Multiple Sclerosis Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 47. Europe Multiple Sclerosis Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 48. China Multiple Sclerosis Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 49. China Multiple Sclerosis Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 50. China Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2019-2024) & (US$ Million)
    Table 51. China Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2025-2030) & (US$ Million)
    Table 52. Asia Multiple Sclerosis Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 53. Asia Multiple Sclerosis Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 54. Asia Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2019-2024) & (US$ Million)
    Table 55. Asia Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2025-2030) & (US$ Million)
    Table 56. Asia Multiple Sclerosis Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 57. Asia Multiple Sclerosis Therapeutics Market Size by Region (2019-2024) & (US$ Million)
    Table 58. Asia Multiple Sclerosis Therapeutics Market Size by Region (2025-2030) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Multiple Sclerosis Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Multiple Sclerosis Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2019-2024) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2025-2030) & (US$ Million)
    Table 63. Middle East, Africa, and Latin America Multiple Sclerosis Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 64. Middle East, Africa, and Latin America Multiple Sclerosis Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 65. Middle East, Africa, and Latin America Multiple Sclerosis Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 66. Novartis Company Details
    Table 67. Novartis Business Overview
    Table 68. Novartis Multiple Sclerosis Therapeutics Product
    Table 69. Novartis Revenue in Multiple Sclerosis Therapeutics Business (2019-2024) & (US$ Million)
    Table 70. Novartis Recent Developments
    Table 71. Teva Pharmaceuticals Company Details
    Table 72. Teva Pharmaceuticals Business Overview
    Table 73. Teva Pharmaceuticals Multiple Sclerosis Therapeutics Product
    Table 74. Teva Pharmaceuticals Revenue in Multiple Sclerosis Therapeutics Business (2019-2024) & (US$ Million)
    Table 75. Teva Pharmaceuticals Recent Developments
    Table 76. Sanofi Genzyme Company Details
    Table 77. Sanofi Genzyme Business Overview
    Table 78. Sanofi Genzyme Multiple Sclerosis Therapeutics Product
    Table 79. Sanofi Genzyme Revenue in Multiple Sclerosis Therapeutics Business (2019-2024) & (US$ Million)
    Table 80. Sanofi Genzyme Recent Developments
    Table 81. Bayer Company Details
    Table 82. Bayer Business Overview
    Table 83. Bayer Multiple Sclerosis Therapeutics Product
    Table 84. Bayer Revenue in Multiple Sclerosis Therapeutics Business (2019-2024) & (US$ Million)
    Table 85. Bayer Recent Developments
    Table 86. Pfizer Company Details
    Table 87. Pfizer Business Overview
    Table 88. Pfizer Multiple Sclerosis Therapeutics Product
    Table 89. Pfizer Revenue in Multiple Sclerosis Therapeutics Business (2019-2024) & (US$ Million)
    Table 90. Pfizer Recent Developments
    Table 91. Biogen Idec Company Details
    Table 92. Biogen Idec Business Overview
    Table 93. Biogen Idec Multiple Sclerosis Therapeutics Product
    Table 94. Biogen Idec Revenue in Multiple Sclerosis Therapeutics Business (2019-2024) & (US$ Million)
    Table 95. Biogen Idec Recent Developments
    Table 96. Merck Company Details
    Table 97. Merck Business Overview
    Table 98. Merck Multiple Sclerosis Therapeutics Product
    Table 99. Merck Revenue in Multiple Sclerosis Therapeutics Business (2019-2024) & (US$ Million)
    Table 100. Merck Recent Developments
    Table 101. AbbVie Company Details
    Table 102. AbbVie Business Overview
    Table 103. AbbVie Multiple Sclerosis Therapeutics Product
    Table 104. AbbVie Revenue in Multiple Sclerosis Therapeutics Business (2019-2024) & (US$ Million)
    Table 105. AbbVie Recent Developments
    Table 106. Research Programs/Design for This Report
    Table 107. Key Data Information from Secondary Sources
    Table 108. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Multiple Sclerosis Therapeutics Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Multiple Sclerosis Therapeutics Market Share by Type: 2023 VS 2030
    Figure 3. Beta Interferon Features
    Figure 4. Corticosteroids Features
    Figure 5. Monoclonal Antibodies Features
    Figure 6. Antineoplastic Agents Features
    Figure 7. Others Features
    Figure 8. Global Multiple Sclerosis Therapeutics Market Size Growth Rate by Distribution Channel, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 9. Global Multiple Sclerosis Therapeutics Market Share by Distribution Channel: 2023 VS 2030
    Figure 10. Hospital Pharmacies Case Studies
    Figure 11. Retail Pharmacies Case Studies
    Figure 12. e-Commerce Case Studies
    Figure 13. Multiple Sclerosis Therapeutics Report Years Considered
    Figure 14. Global Multiple Sclerosis Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 15. Global Multiple Sclerosis Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 16. Global Multiple Sclerosis Therapeutics Market Share by Region: 2023 VS 2030
    Figure 17. Global Multiple Sclerosis Therapeutics Market Share by Players in 2023
    Figure 18. Global Top Multiple Sclerosis Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Sclerosis Therapeutics as of 2023)
    Figure 19. The Top 10 and 5 Players Market Share by Multiple Sclerosis Therapeutics Revenue in 2023
    Figure 20. North America Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 21. North America Multiple Sclerosis Therapeutics Market Share by Type (2019-2030)
    Figure 22. North America Multiple Sclerosis Therapeutics Market Share by Distribution Channel (2019-2030)
    Figure 23. North America Multiple Sclerosis Therapeutics Market Share by Country (2019-2030)
    Figure 24. United States Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. Canada Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. Europe Multiple Sclerosis Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 27. Europe Multiple Sclerosis Therapeutics Market Share by Type (2019-2030)
    Figure 28. Europe Multiple Sclerosis Therapeutics Market Share by Distribution Channel (2019-2030)
    Figure 29. Europe Multiple Sclerosis Therapeutics Market Share by Country (2019-2030)
    Figure 30. Germany Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. France Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. U.K. Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Italy Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Russia Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. Nordic Countries Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. China Multiple Sclerosis Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 37. China Multiple Sclerosis Therapeutics Market Share by Type (2019-2030)
    Figure 38. China Multiple Sclerosis Therapeutics Market Share by Distribution Channel (2019-2030)
    Figure 39. Asia Multiple Sclerosis Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 40. Asia Multiple Sclerosis Therapeutics Market Share by Type (2019-2030)
    Figure 41. Asia Multiple Sclerosis Therapeutics Market Share by Distribution Channel (2019-2030)
    Figure 42. Asia Multiple Sclerosis Therapeutics Market Share by Region (2019-2030)
    Figure 43. Japan Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. South Korea Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. China Taiwan Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Southeast Asia Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. India Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. Australia Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 49. Middle East, Africa, and Latin America Multiple Sclerosis Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 50. Middle East, Africa, and Latin America Multiple Sclerosis Therapeutics Market Share by Type (2019-2030)
    Figure 51. Middle East, Africa, and Latin America Multiple Sclerosis Therapeutics Market Share by Distribution Channel (2019-2030)
    Figure 52. Middle East, Africa, and Latin America Multiple Sclerosis Therapeutics Market Share by Country (2019-2030)
    Figure 53. Brazil Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Mexico Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Turkey Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. Saudi Arabia Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. Israel Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 58. GCC Countries Multiple Sclerosis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 59. Novartis Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2019-2024)
    Figure 60. Teva Pharmaceuticals Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2019-2024)
    Figure 61. Sanofi Genzyme Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2019-2024)
    Figure 62. Bayer Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2019-2024)
    Figure 63. Pfizer Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2019-2024)
    Figure 64. Biogen Idec Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2019-2024)
    Figure 65. Merck Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2019-2024)
    Figure 66. AbbVie Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2019-2024)
    Figure 67. Bottom-up and Top-down Approaches for This Report
    Figure 68. Data Triangulation
    Figure 69. Key Executives Interviewed